Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 3/20 | 0.49 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.39 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 7/20 | 0.39 |
| ▸ | MMP1 | P03956 | 2/20 | 0.39 |
| ▸ | MMP3 | P08254 | 2/20 | 0.39 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7295712 | 0.87 | REN (0.49) | RENCNR1CNR2HDAC3HDAC4 | |
| SCHEMBL7299196 | 0.83 | MMP2 (0.44) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL7292894 | 0.81 | TACR2 (0.49) | RENMMP2 | |
| SCHEMBL7289524 | 0.81 | REN (0.50) | RENCNR1CNR2ALDH1A1MMP2 | |
| SCHEMBL6976760 | 0.80 | REN (0.47) | RENALDH1A1HPGDDUSP3PTPN5 | |
| SCHEMBL7280901 | 0.80 | REN (0.47) | RENALDH1A1HPGDDUSP3PTPN5 | |
| SCHEMBL7426636 | 0.76 | HRH4 (0.53) | RENALDH1A1HPGDDUSP3PTPN5 | |
| SCHEMBL7301583 | 0.73 | HDAC3 (0.45) | CNR1CNR2HDAC3HDAC4HDAC1 | |
| SCHEMBL7293025 | 0.73 | MMP8 (0.55) | ALDH1A1MMP2MMP1MMP3 | |
| SCHEMBL7079946 | 0.72 | REN (0.42) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040087801-A1 | Imidazolyl/benzimidazolyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension | G.D. SEARLE & CO. | 2004-05-06 | — | — | US | disclosed |
| US-20030130329-A1 | Imidazolyl/benzimidazolyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension | G.D. SEARLE & CO. | 2003-07-10 | — | — | US | disclosed |
| US-20020115867-A1 | Imidazolyl/benzimidazolyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension | HANSON GUNNAR J (US) | 2002-08-22 | — | — | US | disclosed |
| EP-0655059-B1 | IMIDAZOLYL/BENZIMIDAZOLYL-TERMINATED ALKYLAMINO ETHYNYL ALANINE AMINO DIOL COMPOUNDS FOR TREATMENT OF HYPERTENSION | SEARLE & CO (US) | 1996-12-18 | — | — | EP | disclosed |
| EP-0655059-A1 | IMIDAZOLYL/BENZIMIDAZOLYL-TERMINATED ALKYLAMINO ETHYNYL ALANINE AMINO DIOL COMPOUNDS FOR TREATMENT OF HYPERTENSION. | SEARLE & CO (US) | 1995-05-31 | — | — | EP | disclosed |
| US-5373017-A | Renin inhibitor | G. D. SEARLE & CO. (US) | 1994-12-13 | — | — | US | disclosed |
| WO-1994004508-A1 | IMIDAZOLYL/BENZIMIDAZOLYL-TERMINATED ALKYLAMINO ETHYNYL ALANINE AMINO DIOL COMPOUNDS FOR TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1994-03-03 | — | — | WO | disclosed |
| US-5063208-A | Cardiovascular disorders, vision defects | ABBOTT LABORATORIES (US) | 1991-11-05 | — | — | US | disclosed |
| EP-0410260-A2 | Peptidyl aminodiol renin inhibitors | ABBOTT LABORATORIES (US) | 1991-01-30 | — | — | EP | disclosed |
| EP-0341602-A2 | Renin-inhibiting functionalized peptidyl aminodiols and - triols | ABBOTT LABORATORIES (US) | 1989-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087801-A1 | Imidazolyl/benzimidazolyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension | REN, AGTR1, AGTR2 | REN 1/4885CNR1 1829/4885CNR2 1619/4885 |
| US-20020115867-A1 | Imidazolyl/benzimidazolyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension | REN, AGT, AGTR1 | REN 1/4885CNR1 1384/4885CNR2 1144/4885 |
| US-20030130329-A1 | Imidazolyl/benzimidazolyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension | REN, AGTR1, AGTR2 | REN 1/4885CNR1 1829/4885CNR2 1619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.